following a full submission:
trastuzumab emtansine (Kadcyla®) is accepted for use within NHSScotland.
Indication under review: As a single agent, for the adjuvant treatment of adult patients with human epidermal growth factor-2 (HER2) positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2 targeted therapy.
Trastuzumab emtansine was associated with a statistically significant improvement in invasive disease-free survival compared with a HER2 targeted agent in patients with HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after completion of neoadjuvant treatment containing a HER2 targeted agent.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- trastuzumab emtansine (Kadcyla)
- SMC ID:
- SMC2298
- Indication:
As a single agent, for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and / or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 November 2020